Global Biosimilars Market 2016 Trends, Opportunities & 2020 Forecasts Discussed in New Research Report Now Available at adds "Global Biosimilar Market: Size, Trends & Forecasts (2016-2020)" report to its research store.

PUNE, India, Nov. 30, 2016 /PRNewswire-iReach/ -- The report entitled "Global Biosimilar Market: Size, Trends & Forecasts (2016-2020)", provides an analysis of global biosimilar market in terms of value. The report also provides a brief analysis of the global biologics market by value and market share by products.

Photo -

Complete report available at

Furthermore, the report also assesses the key opportunities in the market and outlines the factors that are and will be driving the growth of the industry. Growth of the overall global biosimilar market has also been forecasted for the period 2016-2020, taking into consideration the previous growth patterns, the growth drivers and the current and future trends.

Company Coverage of Biosimilar Market:

  • Sandoz
  • Amgen
  • Celltrion
  • Pfizer

Majority of biosimilars are in pipeline as most of the major biologics have either already expired or are about to lose their patent in the next two years which act as a major driving force for the biosimilar market. Four major biologics namely Humira, Enbrel, Remicade and Infliximab patents are set to expire in December 2016, incentivizes a large number of companies to enter into biosimilar market.

The biosimilar market is in its early stages, but is expected to grow in the next five years. The global biosimilar market is supported by various growth drivers such as growing pressure to curtail healthcare expenditure, patent expiries of major biopharmaceuticals, rising chronic disease among aging population and positive outcomes in ongoing clinical trials etc. Yet the market faces some challenges, such as restrict entry of new players, the complexity of manufacturing biosimilars and clinical limitations including patient recruitment obstacles.

Purchase a copy of this research report at

Sandoz, Amgen, Celltrion and Pfizer are some of the key players operating in the global biosimilar market whose company profiling has been done in the report. This segment of the report summarizes business overview, financial overview and the business strategies of the companies.

Major Points from Table of Contents:

1. Executive Summary

2. Introduction
2.1 Overview of Pharmaceutical Industry
2.2 Overview of Biologics
2.2.1 Difference between Chemical Drugs Vs 1st Gen Vs 2nd Gen Biologics
2.2.2 Methods of Biologics Manufacturing
2.2.3 Top 5 Biologics Drugs
2.3 Overview of Biosimilars
2.3.1 Difference between Biosimilars and Generics

3. Global Market Analysis
3.1 Global Pharmaceutical Market Analysis
3.1.1 Global Pharmaceutical Market by Value
3.1.2 Global Pharmaceutical Sales: Biotech Vs Conventional Technology
3.2 Global Biologics Market Analysis
3.2.1 Global Biologics Market by Value
3.2.2 Global Biologics Market Share by Products
3.3 Global Biosimilar Market Analysis
3.3.1 Global Biosimilar Market by Value
3.3.2 Major Biosimilars in the Pipeline

4. Market Dynamics
4.1 Growth Drivers
4.1.1 Growing Pressure to Curtail Healthcare Expenditure
4.1.2 Patent Expiries of Major Biopharmaceuticals
4.1.3 Positive Outcomes in Ongoing Clinical Trials
4.1.4 Rising Demand for Biosimilars in Therapeutic Application
4.1.5 Rising Chronic Disease among Aging Population
4.2 Challenges
4.2.1 Restrict Entry of New Players
4.2.2 Complexity of Expertise
4.2.3 Regulatory Challenges
4.2.4 Market Penetration Issue of Orphan Biosimilars
4.2.5 Clinical Limitations Including Patient Recruitment Obstacles
4.3 Market Trends
4.3.1 Emergence of New Market Participants
4.3.2 Inclusion of Drug Delivery Device
4.3.3 Uberization of Healthcare Industry
4.3.4 Increasing Use of Single-Use Technology

5. Competitive Landscape
5.1 Global Biologics Market Sales by Drugs

6. Company Profiling

Other Related Reports on Biosimilar Market:

Global Biosimilars Market and Forecast (By Product Type, Applications, Country Wise and Companies) to 2021 and Biosimilars Approved and Pipeline Analysis ( The biosimilars are poised to capture an unprecedented position in the biopharmaceutical industry driven by an increased extent of adoption and growing investment and deal making activity globally. The global biosimilars market is predicted to cross US$ 25 Billion mark by 2020.  With the continuous increasing demand for biologics, manufacturers are looking for novel strategies that will help them attain maximum returns on investment. Biosimilars are seen as the key weapon to curbing soaring healthcare costs globally.

Global Biosimilar Market Trends & Opportunities ( Rising budgetary pressures to reduce healthcare expenditures, patent expiries of blockbuster drugs, growing demand for cost-effective alternatives, increasing aging population, conductive government initiatives and rising incidences of various diseases are significant factors that are responsible for the growth of global biosimilar market (2013 to 2018). On the other hand stringent regulatory environment in some countries, high manufacturing complexities, costs, and presence of low priced generic drugs and high-entry barriers are considered to hinder the market growth.

About Us:
MarketReportsOnline comprises of an online library of 2,50,000 reports and in-depth market research studies of over 5000+ micro markets. We provide 24/7 online and offline support to our customers. Get in touch with us for your needs of market research reports. 

Media Contact: Ritesh Tiwari, Market Reports Online, + 1 888 391 5441,

News distributed by PR Newswire iReach:

SOURCE Market Reports Online



Health & Living


Medical Pharmaceuticals, Pharmaceuticals

Need Help